The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada
Open Access
- 6 October 2019
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (5) , 1026-1036
Abstract
Background: Cross‐sectional data on patient burden in adults with atopic dermatitis (AD) from real‐world clinical practice are limited.Objective: This study compared patient‐reported burden associated with adult AD across severity levels from clinical practices in Canada and Europe.Methods: This study included adults (18–65 years) diagnosed with AD by dermatologists, general practitioners or allergists. Participants categorized as mild (n = 547; 37.3%), moderate (n = 520; 35.4%) or severe (n = 400; 27.3%) based on Investigator's Global Assessment completed a questionnaire that included pruritus and pain numerical rating scales, Patient‐Oriented‐Scoring of Atopic Dermatitis (PO‐SCORAD) itch and sleep visual analogue scales, Dermatology Life Quality Index (DLQI), and the Hospital Anxiety and Depression Scale (HADS). Participants were also stratified by inadequate efficacy/intolerance/contraindication to cyclosporine [Cyclo; n = 62 (4 mild, 18 moderate, 40 severe)] and any systemic immunomodulatory agent [IMM; n = 104 (13 mild, 31 moderate, 60 severe)] and compared with the severe group excluding participants identified as Cyclo/IMM.Results: Age was similar across severity groups; the proportion of women was higher in the mild group relative to severe (61.2% vs. 50.5%; P < 0.001). Compared with moderate and mild, participants with severe AD had more comorbidities, higher itch and pain severity, worse sleep and higher levels of anxiety and depression (all P < 0.001). Mean ± SD DLQI score among participants with severe AD (16.2 ± 6.9) showed a large effect on quality of life that was higher than those with moderate (10.2 ± 6.3) and mild (5.5 ± 4.9) (both P < 0.001). The burden among Cyclo and IMM subgroups was generally similar to that of participants with severe AD.Conclusions: Adults with AD reported a substantial burden across multiple domains that was significantly higher in those with severe disease. The burden among participants in the Cyclo/IMM subgroups was similar to those with severe AD.Keywords
Funding Information
- Regeneron Pharmaceuticals
- Sanofi
This publication has 46 references indexed in Scilit:
- Impact of disease severity on work productivity and activity impairment in Japanese patients with atopic dermatitisThe Journal of Dermatology, 2013
- Assessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic PruritusActa Dermato-Venereologica, 2012
- Atopic dermatitis: a disease of altered skin barrier and immune dysregulationImmunological Reviews, 2011
- Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010PLOS ONE, 2011
- Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in EuropeAllergy, 2011
- The Patient-Oriented Eczema MeasureArchives of Dermatology, 2004
- The eczema area and severity index (EASI): assessment of reliability in atopic dermatitisExperimental Dermatology, 2001
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994
- Severity Scoring of Atopic Dermatitis: The SCORAD IndexDermatology, 1993
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983